Reporting from ASCO 2022 Annual Meeting in Chicago, Domenica LORUSSO features the results from 3 trials in Gynaecological Malignancies.
She details findings from the innovaTV-205 trial testing the first-line tisotumab vedotin plus pembrolizumab in recurrent or metastatic Cervical Cancer. She also discusses the results from the MITO 23 study evaluating trabectedin vs clinician's choice of chemotherapy in recurrent Ovarian Cancer, and further comments the results from the ATHENA-MONO trial assessing maintenance rucaparib vs placebo following first-line chemotherapy in Ovarian Cancer.
This video was supported with educational grants from Bayer Healthcare, Novartis and Roche.
The selection of study results covered in this track is exclusively under the responsibility of ESMO and the speakers selected by ESMO.